IL2 and cancer: Furthermore, the group identified as high-risk demonstrated notably lower scores compared to the low-risk group across various cancer hallmark pathways, such as allograft rejection, apoptosis, complement, IL2-STAT5 signaling, inflammatory response, interferon gamma response, peroxisome pathways, and reactive oxygen species pathways.